The ongoing KN026–001 phase II/III trial will further explore the survival benefit of KN026 in combination with chemotherapy as a second-line and beyond treatment in patients with HER2-positive advanced G/GEJ adenocarcinoma. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.